No Data
No Data
Jefferies Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $35
MBX Biosciences Stock Jumps 5% on Clinical Trial Progress
MBX Biosciences | 10-K: FY2024 Annual Report
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025
MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027
MBX Biosciences | 8-K: MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Unlock the Full List